New products
During 2011, the following medicines receive marketing authorization:
Anastrozex (anastrazole)
Fluvastat (fluvastatin)
Pantoprazole-Tchaikapharma (pantoprazole)
Peximir (pramipexole)
Alonzap (olanzapine)
Levor (levofloxacin)
Pipetazon (piperacillin/tazobactam)
Corabace-Co (quinapril/ hydrochlorothiazide)
Irbesso (irbesartan)
Co-Irbesso (irbesartan/hydrochlorothiazide)
Co-Hypertonic (losartan/hydrochlorothiazide)
Asprevent (montelukast)
Klacar powder for solution for infusion (clarithromycin)
Klacar XL (clarithromycin)